Core Insights - Neurocrine Biosciences presented head-to-head data showing that INGREZZA (valbenazine) has significantly higher VMAT2 target occupancy compared to AUSTEDO XR (deutetrabenazine), indicating greater potency in treating hyperkinetic movement disorders [1][3][7] Group 1: Study Findings - The study confirmed that both INGREZZA and AUSTEDO XR engage VMAT2, but INGREZZA demonstrated approximately two-fold higher target occupancy at therapeutic doses [3][4] - The primary analysis showed a least squares mean VMAT2 occupancy of approximately 76.5% for INGREZZA compared to 38.3% for AUSTEDO XR [3][4] - Pharmacokinetic modeling indicated superior VMAT2 engagement at therapeutic doses for INGREZZA, with estimated steady-state occupancy of 83% at 40 mg and 92% at 80 mg, compared to AUSTEDO XR's 54% at 24 mg and 70% at 48 mg [4] Group 2: Clinical Implications - The higher VMAT2 occupancy of INGREZZA may contribute to its robust clinical efficacy observed in multiple trials for tardive dyskinesia and Huntington's disease chorea [3][4] - Both INGREZZA and AUSTEDO XR were generally well tolerated, consistent with their known safety profiles [5] Group 3: Background on Disorders - Tardive dyskinesia (TD) is characterized by uncontrolled movements and affects at least 800,000 adults in the U.S., often as a side effect of antipsychotic medications [8] - Huntington's disease (HD) affects approximately 41,000 adults in the U.S. and is associated with chorea, an involuntary movement disorder [9] Group 4: Product Information - INGREZZA is a selective VMAT2 inhibitor approved for treating adults with tardive dyskinesia and chorea associated with Huntington's disease, offering therapeutic doses from day one without required titration [10][11] - The product is available in capsule forms of 40 mg, 60 mg, and 80 mg, and also in a sprinkle formulation for patients with swallowing difficulties [12][23]